Stifel analyst Christopher Growe maintains Conagra Brands (NYSE:CAG) with a Hold and lowers the price target from $44 to $40.
MiNK Therapeutics’ AgenT-797 Presents Results In The Treatment Of Severe Acute Respiratory Distress, Published In Nature Communications
MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell